These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 26320080)

  • 1. Seletracetam enhances short term depression in vitro.
    Yang X; Meehan AL; Rothman SM; Dubinsky JM
    Epilepsy Res; 2015 Nov; 117():17-22. PubMed ID: 26320080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brivaracetam augments short-term depression and slows vesicle recycling.
    Yang X; Bognar J; He T; Mohammed M; Niespodziany I; Wolff C; Esguerra M; Rothman SM; Dubinsky JM
    Epilepsia; 2015 Dec; 56(12):1899-909. PubMed ID: 26515103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levetiracetam has an activity-dependent effect on inhibitory transmission.
    Meehan AL; Yang X; Yuan LL; Rothman SM
    Epilepsia; 2012 Mar; 53(3):469-76. PubMed ID: 22292611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission.
    Yang XF; Weisenfeld A; Rothman SM
    Epilepsia; 2007 Oct; 48(10):1861-9. PubMed ID: 17521346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levetiracetam accelerates the onset of supply rate depression in synaptic vesicle trafficking.
    García-Pérez E; Mahfooz K; Covita J; Zandueta A; Wesseling JF
    Epilepsia; 2015 Apr; 56(4):535-45. PubMed ID: 25684406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy.
    Matagne A; Margineanu DG; Potschka H; Löscher W; Michel P; Kenda B; Klitgaard H
    Eur J Pharmacol; 2009 Jul; 614(1-3):30-7. PubMed ID: 19383493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seletracetam (ucb 44212) inhibits high-voltage-activated Ca2+ currents and intracellular Ca2+ increase in rat cortical neurons in vitro.
    Martella G; Bonsi P; Sciamanna G; Platania P; Madeo G; Tassone A; Cuomo D; Pisani A
    Epilepsia; 2009 Apr; 50(4):702-10. PubMed ID: 19055493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam.
    Meehan AL; Yang X; McAdams BD; Yuan L; Rothman SM
    J Neurophysiol; 2011 Sep; 106(3):1227-39. PubMed ID: 21653714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levetiracetam inhibits endocytosis and augments short-term depression.
    Pharmazie; 2018 Nov; 73(11):643-646. PubMed ID: 30396382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Sands ZA; Vandenplas C; Gillard M
    Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cortico-hippocampal hyperexcitability in synapsin I/II/III knockout mice: age-dependency and response to the antiepileptic drug levetiracetam.
    Boido D; Farisello P; Cesca F; Ferrea E; Valtorta F; Benfenati F; Baldelli P
    Neuroscience; 2010 Nov; 171(1):268-83. PubMed ID: 20804820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically relevant concentrations of ketamine mainly affect long-term potentiation rather than basal excitatory synaptic transmission and do not change paired-pulse facilitation in mouse hippocampal slices.
    Ribeiro PO; Tomé AR; Silva HB; Cunha RA; Antunes LM
    Brain Res; 2014 Apr; 1560():10-7. PubMed ID: 24637258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levetiracetam has a time- and stimulation-dependent effect on synaptic transmission.
    Yang XF; Rothman SM
    Seizure; 2009 Nov; 18(9):615-9. PubMed ID: 19651528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy.
    Pollard JR
    Curr Opin Investig Drugs; 2008 Jan; 9(1):101-7. PubMed ID: 18183537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid withdrawal for 4 days prevents synaptic depression induced by low dose of morphine or naloxone in rat hippocampal CA1 area in vivo.
    Dong Z; Han H; Cao J; Xu L
    Hippocampus; 2010 Feb; 20(2):335-43. PubMed ID: 19437411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Gillard M
    Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
    Sanon NT; Gagné J; Wolf DC; Aboulamer S; Bosoi CM; Simard A; Messiet E; Desgent S; Carmant L
    Epilepsy Behav; 2018 Feb; 79():117-125. PubMed ID: 29287214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.